Return on Investment (ROI) Analysis Facilitates Launch of Adherence Program
| Industry | Pharmaceutical Manufacturer |
| Problem | A manufacturer was evaluating a pilot program with a major pharmacy chain to increase adherence through pharmacist counseling coupled with a copay reduction program. The project goal was to determine if the program’s estimated ROI would be satisfactory and to create a business case analysis to receive approval to launch the program. |
| PHSI Solution | Using experience from previous adherence programs along with data provided by the pharmacy chain, a ROI analysis was tailored specifically for the proposed program. PHSI identified intervention metrics and the potential number of patients eligible for the program based on the inclusion criteria agreed upon. PHSI estimated fixed and variable program costs and a calculated ROI for the manufacturer. |
| Results | The business case analysis and ROI analysis allowed the manufacturer to go forward with the program and secure funding from the brand team based upon the expected program costs. |
Poll Results
August 2023 Question of the Month
What steps do you take when learning about an electronic prescribing challenge?
Root cause analysis: 0%
Compendia review: 0%
Engage a partner: 0%
All of the above: 50%
None of the above: 50%
July 2023 Question of the Month
Does your organization have a strategy for Humira biosimilar launches?
Yes, well defined: 0%
We have a framework: 50%
Waiting for clarity: 0%
No: 0%
Unaware of need: 50%
June 2023 Question of the Month
How far in advance of NDA/BLA expected approval do (or should) manufacturers begin planning their compendia submission strategy?
During Phase II Trials: 0%
Initiation of Phase III Trials: 66%
6 months prior to approval: 33%
3 months prior to approval: 0%
At time of approval: 0%
After approval: 0%
No strategy: 0%
Contact
968 Perry Highway
Pittsburgh, PA 15237
Get Directions »
Phone: (412) 635-4650
Follow/Subscribe:
